Holen Sie sich die Stockscreener-App
45.38
0.70%
-0.32
Handel nachbörslich:
45.38
Schlusskurs vom Vortag:
$45.70
Offen:
$46.03
24-Stunden-Volumen:
403.79K
Relative Volume:
0.87
Marktkapitalisierung:
$2.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.57M
KGV:
-23.68
EPS:
-1.9166
Netto-Cashflow:
$-72.14M
1W Leistung:
-0.68%
1M Leistung:
+7.59%
6M Leistung:
+4.56%
1J Leistung:
+137.59%
1-Tages-Spanne:
$45.10
$47.89
1-Wochen-Bereich:
$43.41
$48.00
52-Wochen-Spanne:
$16.38
$51.56
Sionna Therapeutics Inc Stock (SION) Company Profile
Firmenname
Sionna Therapeutics Inc
Sektor
Branche
Telefon
617-819-2020
Adresse
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
45.38 | 2.06B | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-04 | Eingeleitet | Guggenheim | Buy |
| 2025-03-04 | Eingeleitet | Stifel | Buy |
| 2025-03-04 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
SION|SION|Price:45.700|Chg%:+1.640 - TradingKey
Sionna Therapeutics Slides as Lofty Valuation Deflates - TipRanks
Sionna Therapeutics Inc. (SION) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SION Jumps As Sionna Therapeutics Stock Extends Breakout - StocksToTrade
SION Jumps As Sionna Therapeutics Draws Trader Attention - StocksToTrade
Sionna Therapeutics (SION) Sees 9.2% Surge in Stock Price - GuruFocus
Sionna Therapeutics stock hits all-time high at 48.66 USD - Investing.com
Sionna Therapeutics stock hits all-time high at 48.66 USD By Investing.com - Investing.com South Africa
Sionna Therapeutics Surges As CF Trial Data Loom - TipRanks
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. Common Stock (SION) Stock Price Today: $42.59 - Gotrade
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics(SION.US) Director Sells US$3.85 Million in Common Stock - Moomoo
Form 4 Sionna Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
OrbiMed Advisors, Sionna director, sells $3.85 million in stock - Investing.com UK
Sionna Therapeutics director Peter Thompson sells $3.85m in stock - Investing.com
Sionna Therapeutics Insider Sold Shares Worth $3,854,281, According to a Recent SEC Filing - Moomoo
Sionna Therapeutics director Peter Thompson sells $3.85m in stock By Investing.com - Investing.com Canada
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock - Investing.com
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock By Investing.com - Investing.com Nigeria
Form 4 Sionna Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Is Sionna Therapeutics (SION) Undervalued Or Already Priced In As Index Changes Draw Focus? - simplywall.st
ETFs Investing in Sionna Therapeutics, Inc. Stocks - TradingView
SIONSionna Therapeutics Inc Options - Finviz
Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics director Thompson sells $5.27m in stock By Investing.com - Investing.com South Africa
Sionna Therapeutics director Thompson sells $5.27m in stock - Investing.com
Sionna Therapeutics Inc. (SION) Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates Amid No RevenueROE Trend Analysis - dars.gov.et
Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to EBIT forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION) - Seeking Alpha
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell 3000E Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION) - TradingView
SION Forecast — Price Target — Prediction for 2027 - TradingView
JonesTrading Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com - Investing.com Nigeria
Guggenheim Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sionna Therapeutics: Buy Rating Reiterated on NBD1-Focused CF Strategy; $60 Price Target Maintained - TipRanks
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor - The Globe and Mail
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Finanzdaten der Sionna Therapeutics Inc-Aktie (SION)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):